Drug Trial Radar · NCT06963021
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 30, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Conditions
- Major Depressive Disorder
Interventions
OsavampatorDrug
Osavampator tablets
PlaceboDrug
Matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Chino, California · Recruiting
Neurocrine Clinical Site
Los Angeles, California · Recruiting
Neurocrine Clinical Site
Stanford, California · Recruiting
Neurocrine Clinical Site
Aurora, Colorado · Recruiting
Neurocrine Clinical Site
Cromwell, Connecticut · Active not recruiting
Neurocrine Clinical Site
Farmington, Connecticut · Active not recruiting
Neurocrine Clinical Site
Maitland, Florida · Recruiting
Neurocrine Clinical Site
Miami, Florida · Recruiting
Neurocrine Clinical Site
Tampa, Florida · Withdrawn
Neurocrine Clinical Site
Skokie, Illinois · Recruiting
Neurocrine Clinical Site
Gaithersburg, Maryland · Active not recruiting
Neurocrine Clinical Site
Las Vegas, Nevada · Recruiting
Neurocrine Clinical Site
Las Vegas, Nevada · Recruiting
Neurocrine Clinical Site
Cherry Hill, New Jersey · Recruiting
Neurocrine Clinical Site
Cedarhurst, New York · Recruiting
Neurocrine Clinical Site
New York, New York · Active not recruiting
Neurocrine Clinical Site
New York, New York · Recruiting
Neurocrine Clinical Site
Charlotte, North Carolina · Recruiting
Neurocrine Clinical Site
Philadelphia, Pennsylvania · Recruiting
Neurocrine Clinical Site
Alken, Belgium · Active not recruiting
Neurocrine Clinical Site
Bruges, Belgium · Recruiting
Neurocrine Clinical Site
Mechelen, Belgium · Recruiting
Neurocrine Clinical Site
Verdun, Canada · Recruiting
Neurocrine Clinical Site
Toronto, Ontario, Canada · Recruiting
Neurocrine Clinical Site
Kuopio, Finland · Recruiting
Neurocrine Clinical Site
Oulu, Finland · Recruiting
Neurocrine Clinical Site
Tampere, Finland · Recruiting
Neurocrine Clinical Site
Budapest, Hungary · Recruiting
Neurocrine Clinical Site
Budapest, Hungary · Recruiting
Neurocrine Clinical Site
Budapest, Hungary · Recruiting
Neurocrine Clinical Site
Gyöngyös, Hungary · Recruiting
Neurocrine Clinical Site
Kalocsa, Hungary · Active not recruiting
Neurocrine Clinical Site
Jelgava, Latvia · Recruiting
Neurocrine Clinical Site
Liepāja, Latvia · Recruiting
Neurocrine Clinical Site
Sigulda, Latvia · Recruiting
Neurocrine Clinical Site
London, United Kingdom · Recruiting
Neurocrine Clinical Site
Salford, United Kingdom · Recruiting
Neurocrine Clinical Site
Sheffield, United Kingdom · Recruiting
Neurocrine Clinical Site
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.